Although VM by HT1080 has been demonstrated by expressing green fluorescent protein in them [28], it cannot be ruled out that any abnormal TECs lacking accepted EC markers, e.g. after endothelial-mesenchymal transition, and showing a similar subcellular distribution of NRP1 and MET, may build up ATVs, which would likewise be targeted by rhodocetin-αβ in a tumor-selective manner. The gene discussed is MET; the disease is neoplasm.